Hypertension Prevalence and Control at Trial Entry in the REPRIEVE Study Population: Results From a Secondary Analysis
Year: 2026
Type: article
Abstract: Background: We evaluated baseline hypertension prevalence and control and risk of major adverse cardiovascular events (MACEs) among people with HIV in REPRIEVE who had low to moderate traditional cardiovascular disease (CVD) risk. Methods: Hypertension at baseline was defined by (1) a preexisting diagnosis regardless of antihypertensive treatment or (2) systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg without a prior diagnosis. We estimated the prevalence of the composite hypertension and control outcomes and calculated adjusted prevalence ratios controlling for traditional CVD risk factors using log binomial regression. We explored the relationship between hypertension and MACE using cause-specific Cox proportional hazards models. Results: Of 7769 participants enrolled from 5 regions, the median age was 50 years, and 2419 (31%) were women. The prevalence of baseline hypertension was 36% (n = 2780) with geographic variation. Among these, 1911 (69%) individuals had a preexisting hypertension diagnosis; the remainder (n = 869, 31%) were undiagnosed. Region and traditional CVD risk factors were associated with hypertension prevalence, with obese and overweight body mass index having the highest adjusted prevalence ratios (1.80 [95% CI, 1.67-1.95] and 1.38 [95% CI, 1.28-1.49], respectively). Among those with preexisting hypertension, 40% were uncontrolled, with regional variation. Hypertension at baseline was associated with an increased hazard of MACE (hazard ratio, 2.00; 95% CI, 1.57-2.55) and key components of MACE, including myocardial infarction and stroke. Conclusions: Approximately 1 in 3 REPRIEVE participants had hypertension at baseline. Hypertension was frequently suboptimally controlled. These findings highlight the need for improved screening and optimized treatment of hypertension in people with HIV.
Source: Open Forum Infectious Diseases
DOI: 10.1093/ofid/ofag507
Authors: Risa Hoffman, Maya Watanabe, Esteban Martínez, Markella V Zanni, Anton Pozniak, Saate S Shakil, Sara McCallum, Sarah M Chu, Suman Srinivasa, Carlos D Malvestutto, Carl J Fichtenbaum, Gerald S Bloomfield, Alex B Lu, Judith A Aberg, Judith S Currier, Michael T Lu, Pamela S Douglas, Heather J Ribaudo, Steven K Grinspoon
Institutions: University of California, Los Angeles, Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Centro de Investigación Biomédica en Red Enfermedades Infecciosas, Universitat de Barcelona, Harvard University, Massachusetts General Hospital, Chelsea and Westminster Hospital NHS Foundation Trust, London School of Hygiene & Tropical Medicine, Chelsea and Westminster Hospital, The Ohio State University Wexner Medical Center, The Ohio State University, University of Cincinnati, Duke University, Icahn School of Medicine at Mount Sinai, Duke Medical Center
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,053
Awards: REPRIEVE - CCC - Lead Application, Impacto de la hipertensión arterial en personas con VIH-1 (estudio VIHTA). Subproyecto 1: Análisis de la patología subclínica de órganos diana mediante pruebas complementarias y de imagen., UCLA AIDS Prevention and Treatment Clinical Trials Unit, REPRIEVE - DCC, G4805367024, G6604584082, Columbia Collaborative HIV/AIDS Clinical Trials Unit, G7569665798, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, 1/2 REPRIEVE Extension for Trial Completion, AIDS Clinical Trial Group Laboratory Center, Pitt-Ohio State Clinical Trials Unit, Columbia Collaborative HIV/AIDS Clinical Trials Unit, Boston Area Nutrition Obesity Research Center (NORC), 2/2 REPRIEVE Extension for Trial Completion
OpenAlex ID: W7203950374